---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-120261"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T05:35:52.441593+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q1 net revenue $11.3M; net loss narrows to $16.3M; targets 1H 2025 profitability

## Summary
- PEMGARDA net product revenue of $11.3M in Q1 2025, down from $13.8M in Q4 2024 due to sales force transition; re-acceleration seen in Q2 2025.
- Net loss of $16.3M ($0.14 per share) vs $43.5M ($0.38) a year ago; R&D expenses fell to $10.6M from $31.2M.
- Cash and equivalents $48.1M as of March 31 2025; secured $30M non-dilutive term loan facility with Silicon Valley Bank in April 2025.
- FDA declined EUA expansion request for PEMGARDA as a treatment in Feb 2025 but provided potential near-term pathway for VYD2311.
- VYD2311 Phase 1 data read-out (potency, half-life, safety) anticipated later in Q2 2025; pipeline expansion into RSV and measles underway.

## SEC filing metadata
- accession: 0001193125-25-120261
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/0001193125-25-120261-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312525120261/d66861d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-120261
- JSON: https://secwatch.observer/filing/0001193125-25-120261.json
- Plain text: https://secwatch.observer/filing/0001193125-25-120261.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.